262
Participants
Start Date
January 31, 2007
Primary Completion Date
February 29, 2008
Study Completion Date
February 29, 2008
Rivastigmine 5 cm^2 transdermal patch
Rivastigmine 5 cm\^2 patch size, loaded with 9 mg and providing 4.6 mg rivastigmine per 24 hours.
Rivastigmine 10 cm^2 transdermal patch
Rivastigmine 10 cm\^2 patch size loaded with 18 mg and providing 9.5 mg rivastigmine per 24 hours.
Eastside Comprehensive Medical Center, New York
Neurobehavioral Research, Inc, Cedarhurst
The Clinical Trial Center, Jenkintown
Medical Associates of North Georgia, Cumming
Medical Associates of North Georgia, Canton
Berma Research Group, Hialeah
Sunrise Clinical Research, Hollywood
Premiere Research Institute @ Palm Beach Neurology, West Palm Beach
Center for Clinical Trials, Venice
The Ohio State University, Columbus
Investigative site, Centerville
Witham Health Services, Lebanon
Rochester Center For Behavioral Medicine, Rochester Hills
Senior Adults Specialty Research, Austin
Investigative site, Denver
Dedicated Clinical Research, Sun City
ATP Clinical Research, Costa Mesa
Margolin Brain Institute, Fresno
Investigative site, Eugene
Investigative site, Pittsfield
Alzheimer's Research Corporation, Manchester
Investigative site, Long Branch
Investigative site, Bennington
Lead Sponsor
Novartis
INDUSTRY